NeuroPace ‘commends’ CMS for maintaining FY25 epilepsy reimbursement structure

NeuroPace (NPCE) issued the following statement in response to the Centers for Medicare & Medicaid Services electing not to finalize its proposed reassignment of epilepsy with neurostimulator cases in the FY 2026 Inpatient Prospective Payment System, IPPS, rule. “We appreciate CMS’ openness to public comment on the proposed rule and its reconsideration of the original proposal to reassign RNS cases to MS-DRG 020-022. We commend CMS’ decision to maintain the current MS-DRG assignment for RNS System procedures under MS-DRG 023,” said Joel Becker, Chief Executive Officer of NeuroPace. “This maintains continuity for hospitals providing the RNS System to Medicare beneficiaries, who represent a vulnerable and underserved epilepsy population.”